Methods: We included randomized clinical trials that compared biologics and small-molecule drugs in the treatment of axSpA patients. The primary outcomes assessed were efficacy, including the Assessment of SpondyloArthritis International Society (ASAS) improvement of 20% (ASAS20) ...
biologics small molecule drugs biosimilars antibody-drug conjugates patient access to drugs drug cost 1. Introduction Man has had a long and excruciating experience with ill-health or disease ([1]). In the same vein has been the struggle for cures, a quest that will continue for as long as...
Dupilumab and JAK inhibitors are leading the way in atopic dermatitis treatment, but there are numerous clinical trials of both new biologics and new small molecule drugs, and future treatment regimens likely will utilize both. Although the pathophysiology of atopic dermatitis (AD) is being ...
Small-molecule drugs are chemical compounds with a molecular weight in the range of 0.1–1kDa. They are smaller than biologics or bio-therapeutic modalities, which are generally more than 1kDa in molecular size, as shown inFig. 6.2. Owing to the small size, they possess an advantage over ...
Challenges of general safety evaluations of bio- logics compared to small molecule pharmaceuticals in animal models. Expert Opin Drug Discov. 2010;5(1):79-94.Dixit R, Iciek LA, McKeever K et al (2010) Challenges of general safety evaluations of biologics compared to small molecule ...
Unfortunately, it’s not that simple. The workflows for biologics are in fact much different than the workflows for small molecule drugs. Details Surrounding Biologic Therapeutic Development As always, the devil is in the details, and the details surrounding biologics are much more complex than with...
Eleven COVID-19 therapeutic drug therapies are currently available globally, including eight injectable drug therapies and three oral drugs, with two drug submitted to NDA. The COVID-19 drugs available in the U.S. include four small molecule drugs and four neutralizing antibody therapies. Type Dr...
revealing that the binding of PC786 with S protein substantially affects S protein binding to the ACE2 domain. Lee et al. showed that both Etravirine and Dolutegravir preferentially bind to primary ACE2-interacting residues on the RBD domain, implying that these two drugs may inhibit attachment ...
Moreover, SecA meets also the other criteria that are considered to be desirable for a drug target:7 its function and structure are well understood; it exists in a membrane-bound state that might be more easily accessible to drugs; it is stable in vitro and amenable to high-throughput ...
compromising signalling and inhibiting the functions of TNF in vitro and in vivo. This discovery paves the way for a class of small molecule drugs capable of modulating TNF function by stabilising a naturally sampled, receptor-incompetent conformation of TNF. Furthermore, this approach may prove to...